Neurona Therapeutics Raises $102 Million for Epilepsy Phase 3 Trial
Deal News | Apr 03, 2025 | Column Group LLC/The
Neurona Therapeutics, a company dedicated to developing regenerative cell therapies for nervous system disorders, announced the completion of an oversubscribed $102 million financing round. The financing saw participation from Fidelity Management & Research Company, The Column Group, Soleus Capital, Viking Global Investors, and Cormorant Asset Management, among others. The funds will be utilized to advance Neurona's lead candidate, NRTX-1001, into a Phase 3 trial aimed at treating drug-resistant mesial temporal lobe epilepsy (MTLE). The Phase 3 EPIC trial, backed by FDA alignment, follows promising results from ongoing Phase 1/2 trials that demonstrated significant seizure reductions and no adverse cognitive effects. Neurona aims to support Biologics License Application submission based on the upcoming trial data.
Sectors
- Biotechnology
- Pharmaceuticals
Geography
- United States – Neurona Therapeutics is based in South San Francisco, California, and the trials discussed involve US regulatory bodies like the FDA.
Industry
- Biotechnology – The article discusses Neurona Therapeutics, a company involved in biotechnology, particularly in developing regenerative cell therapies for nervous system disorders.
- Pharmaceuticals – The funding supports advancing Neurona's biotherapeutics pipeline, including NRTX-1001, for epilepsy treatment, a typical focus area of the pharmaceutical industry.
Financials
- $102 million – Total funds raised in the oversubscribed financing round.
- $120 million – Funding previously raised by Neurona in February 2024.
- $8.0 million – Grant provided by the California Institute for Regenerative Medicine.
Participants
| Name | Role | Type | Description |
|---|---|---|---|
| Neurona Therapeutics | Target Company | Company | A biotherapeutics company developing regenerative cell therapies for nervous system disorders. |
| The Column Group | Investor | Company | A venture capital firm that participated in Neurona Therapeutics' financing round. |
| Fidelity Management & Research Company | Investor | Company | An investment management company that participated in the financing round. |
| Soleus Capital | Investor | Company | Investment firm involved in the oversubscribed financing of Neurona Therapeutics. |
| Viking Global Investors | Investor | Company | An investment firm participating in Neurona's financing round. |
| Cormorant Asset Management | Investor | Company | Asset management firm involved in Neurona's financing. |
| U.S. Food and Drug Administration (FDA) | Regulatory Body | Government | Provides regulatory oversight, granted RMAT designation to Neurona's product. |